Quantcast
Last updated on April 17, 2014 at 10:37 EDT

Latest Idenix Pharmaceuticals Inc. Stories

2011-02-14 15:05:00

CAMBRIDGE, Mass., Feb. 14, 2011 /PRNewswire/ -- Idenix Pharmaceuticals, Inc., (Nasdaq: IDIX) announced today that it will report its financial results for the fourth quarter and year end of 2010 on Monday, February 28, 2011 after U.S. financial markets close. Idenix management will host a conference call at 4:30 p.m. ET on Monday, February 28, 2011 to discuss the company's financial results for the fourth quarter and year end of 2010 and provide an update on the company's development...

2011-02-09 16:00:00

CAMBRIDGE, Mass., Feb. 9, 2011 /PRNewswire/ -- Idenix Pharmaceuticals, Inc. (Nasdaq: IDIX), a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, today announced updates to three clinical development programs. IDX184, a liver-targeted HCV nucleotide prodrug The U.S. Food and Drug Administration (FDA) has verbally informed Idenix that the full clinical hold for IDX184 has been removed. The program has been placed on...

2010-11-23 07:00:00

CAMBRIDGE, Mass., Nov. 23, 2010 /PRNewswire-FirstCall/ -- Idenix Pharmaceuticals, Inc. (Nasdaq: IDIX), a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, today announced that the Company will receive a payment of $20 million from the ViiV Healthcare Company for the achievement of a clinical milestone relating to GSK2248761 (known as '761). ViiV Healthcare is developing '761, a drug candidate for the treatment of...

2010-10-29 15:05:00

CAMBRIDGE, Mass., Oct. 29 /PRNewswire-FirstCall/ -- Idenix Pharmaceuticals, Inc. (Nasdaq: IDIX), a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, today reported unaudited financial results for the third quarter and nine months ended September 30, 2010. At September 30, 2010, Idenix's cash and cash equivalents totaled $37.0 million. Third Quarter 2010 Financial Results For the third quarter ended September 30, 2010,...

2010-10-28 08:00:00

CAMBRIDGE, Mass., Oct. 28 /PRNewswire-FirstCall/ -- Idenix Pharmaceuticals, Inc. (Nasdaq: IDIX), announced today that Ronald C. Renaud, Jr. has been elected as President, Chief Executive Officer and a member of the board of directors of the company. Mr. Renaud has served as the company's Chief Financial Officer and Treasurer since June 2007 and Chief Business Officer since June 2010. Prior to joining Idenix in 2007, Mr. Renaud served as Senior Vice President and Chief Financial Officer...

2010-10-27 15:05:00

CAMBRIDGE, Mass., Oct. 27 /PRNewswire-FirstCall/ -- Idenix Pharmaceuticals, Inc. (Nasdaq: IDIX) announced today that the Company will hold an Analyst Day event during the upcoming 61st Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) on Saturday, October 30, 2010 from 9:00 a.m. to 12:00 p.m. ET at the Mandarin Oriental, Boston. The live and archived webcast of the presentation can be accessed under "Calendar of Events" in the Idenix Investor Center at...

2010-10-01 08:55:00

CAMBRIDGE, Mass., Oct. 1 /PRNewswire-FirstCall/ -- Idenix Pharmaceuticals, Inc. (Nasdaq: IDIX), a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, today announced that three abstracts have been accepted for presentation at the 61st Annual Meeting of the American Association for the Study of Liver Diseases (AASLD, October 29-November 2, 2010 in Boston, Massachusetts). The abstracts being presented are on three of the...

2010-09-20 15:17:00

CAMBRIDGE, Mass., Sept. 20 /PRNewswire-FirstCall/ -- Idenix Pharmaceuticals, Inc. (Nasdaq: IDIX) announced today that Idenix management will present a corporate overview at the JMP Securities Healthcare Conference on Monday, September 27, 2010 at 10:30 a.m. ET at the Palace Hotel, New York City; the William Blair & Co. 2nd Annual Biotechnology Summit on Monday, October 4, 2010 at 4:45 p.m. at the InterContinental New York Barclay, New York City; Citi's 5th Annual Biotech Day on Tuesday,...

2010-09-07 15:05:00

CAMBRIDGE, Mass., Sept. 7 /PRNewswire/ -- Idenix Pharmaceuticals, Inc. (Nasdaq: IDIX) announced today that Idenix management will present a corporate overview at the Robert W. Baird Small Cap Healthcare Conference on Tuesday, September 14, 2010 at 9:30 a.m. ET at the St. Regis Hotel, New York City and at the Stifel Nicolaus Healthcare Conference on Thursday, September 16, 2010 at 11:30 a.m. ET at the Four Seasons Hotel, Boston. The live and archived webcast of the company presentation can...

2010-09-07 06:00:00

CAMBRIDGE, Mass., Sept. 7 /PRNewswire-FirstCall/ -- Idenix Pharmaceuticals, Inc. (Nasdaq: IDIX), a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, today announced that the company received verbal notice on Friday, September 3, 2010 from the U.S. Food and Drug Administration (FDA) that the IDX184 and IDX320 programs have been placed on clinical hold. A clinical hold is an order issued by the FDA to the sponsor to delay...